NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a significant regulatory milestone with the National Medical Products Administration’s (NMPA) marketing approval for its JETSTREAM vascular plaque rotary cutting system. This development marks a significant step forward in the treatment of peripheral arterial disease (PAD) in China.
The JETSTREAM system stands out as a sophisticated tool for peripheral arterial plaque resection, designed to reduce lesion volume through its active suction and perfusion capabilities. Engineered to tackle a variety of lesion types, including fibrous and calcified plaques, the system is poised to enhance the efficacy of percutaneous endovascular interventions for primary femoral and popliteal artery lesions, thereby improving blood vessel patency.
Clinical data from real-world applications have demonstrated the JETSTREAM system’s remarkable surgical success rate, with 98.3% of patients achieving postoperative residual stenosis of 30% or less. Furthermore, the system has shown an 86% immediate improvement in luminal area post-surgery. When paired with drug-coated balloons (DCB), the JETSTREAM system has exhibited a target lesion revascularization (TLR) rate of 91% at the 18-month mark, underscoring its potential for long-term patient outcomes.
Boston Scientific’s JETSTREAM system has already garnered registrations across various regions, including Europe and the Asia-Pacific, highlighting its global acceptance and the company’s commitment to advancing medical technology for better patient care. With this latest approval, the JETSTREAM system is set to make a significant impact on the Chinese market, offering a new standard of care for PAD patients.- Flcube.com
